公开(公告)号：US20230268026A1

公开(公告)日：2023-08-24

申请号：US18046849

申请日：2022-10-14

Applicant: ABSCI CORPORATION

Inventor： Roberto Spreafico ,  Goran Rakocevic ,  Ariel Schwartz ,  Joshua Meier

IPC: G16B20/30 ,  G06N3/08 ,  G16B20/20 ,  G16B40/20

CPC classification number: G16B20/30 ,  G06N3/08 ,  G16B20/20 ,  G16B40/20

Abstract: A computing system includes a processor and a memory having stored thereon a trained machine-learned model and instructions that, when executed by the one or more processors, cause the computing system to process a biomolecule sequence variant to predict binding characteristics, identify biomolecule sequence variants of interest; and provide the biomolecule sequence variants of interest as output. A computer-implemented method for training a machine learning model to identify biomolecule sequence variants of interest includes generating biomolecule sequence variants, receiving screening data; and training the machine learning model to predict binding characteristics of an input biomolecule sequence variant. A computing system includes a processor; and a non-transitory computer-readable media having stored thereon a machine-learned model trained using training data and instructions that, when executed by the one or more processors, cause the computing system to: process one or more input biomolecule sequence variants; and provide a predicted naturalness characteristics as output.

公开(公告)号：US12134655B2

公开(公告)日：2024-11-05

申请号：US17606246

申请日：2020-04-29

Applicant: Absci Corporation

Inventor： Daniele Biasci ,  Goran Rakocevic ,  Berke Cagkan Toptas ,  Ines De Santiago Domingos De Jesus

IPC: C07K16/00 ,  C07K16/30 ,  C07K16/32

Abstract: The disclosure herein relates to novel cancer-associated antibodies and antigen-binding fragments that are used in the diagnosis of a cancer or a metastasis thereof. The disclosure herein relates to novel cancer-associated antibodies and antigen-binding fragments that are used in the treatment of a cancer or a metastasis thereof. The disclosure herein relates to novel chimeric antigen receptor or a T cell receptor fusion protein that comprise one or more cancer-associated antigen-binding domains that are useful for the treatment of a cancer.